View on Pubmed.gov 27483122 | View on doi.org 10.1080/1475636...
N-(2-hydroxyphenyl)-2-propylpentanamide, a valproic acid aryl derivative designed in silico with improved anti-proliferative activity in HeLa, rhabdomyosarcoma and breast cancer cells.
- a Laboratorio de Modelado Molecular y Bioinformática , Laboratorio de Bioquímica, Laboratorio de Biofísica y Biocatálisis, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional , Plan de San Luis y Díaz Mirón, Ciudad de México , México.
- b División de Investigación Básica, Instituto Nacional de Cancerología , Tlalpan, Sección XVI, Ciudad de México , México.
- c Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México/Instituto Nacional de Cancerología , Ciudad de México , México.
- d Laboratorio de Oncología Molecular y Estrés Oxidativo , Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional , Plan de San Luis y Díaz Mirón, Ciudad de México , México.
- e Laboratorio de Oncología Experimental , Instituto Nacional de Pediatría , Coyoacán, Insurgentes Cuicuilco, Ciudad de México , México , and.
- f Unidad Profesional Interdisciplinaria de Biotecnología, Instituto Politécnico Nacional , Barrio La Laguna Ticomán, Ciudad de México , México.
Abstract
Epigenetic alterations are associated with cancer and their targeting is a promising approach for treatment of this disease. Among current epigenetic drugs, histone deacetylase (HDAC) inhibitors induce changes in gene expression that can lead to cell death in tumors. Valproic acid (VPA) is a HDAC inhibitor that has antitumor activity at mM range. However, it is known that VPA is a hepatotoxic drug. Therefore, the aim of this study was to design a set of VPA derivatives adding the arylamine core of the suberoylanilide hydroxamic acid (SAHA) with different substituents at its carboxyl group. These derivatives were submitted to docking simulations to select the most promising compound. The compound 2 (N-(2-hydroxyphenyl)-2-propylpentanamide) was the best candidate to be synthesized and evaluated in vitro as an anti-cancer agent against HeLa, rhabdomyosarcoma and breast cancer cell lines. Compound 2 showed a better IC (μM range) than VPA (mM range) on these cancer cells. And also, 2 was particularly effective on triple negative breast cancer cells. In conclusion, 2 is an example of drugs designed in silico that show biological properties against human cancer difficult to treat as triple negative breast cancer.
References
Cited by 38 citations (total)
Journal Article
Untargeted LC-MS/MS Metabolomics Study of HO-AAVPA and VPA on Breast Cancer Cell Lines.
Electronic publication date November 1, 2023
Alan Rubén Estrada-Pérez [...] José Correa-Basurto et al.
Breast cancer (BC) is one of the biggest health problems worldwide, characterized by intricate metabolic and biochemical complexities stemming from...
Journal Article
-(2-Hydroxyphenyl)-2-Propylpentanamide (HO-AAVPA) Induces Apoptosis and Cell Cycle Arrest in Breast Cancer Cells, Decreasing GPER Expression.
Electronic publication date August 10, 2024
Berenice Prestegui Martel [...] José Correa Basurto et al.
In this work, we performed anti-proliferative assays for the compound -(2-hydroxyphenyl)-2-propylpentanamide (HO-AAVPA) on breast cancer (BC) cells (MCF-7, SKBR3, and...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
Substances
- •
- •
- •
- •
- •
- •
- •